BACKGROUND: The inclusion of hepatitis B core antibody-positive (HBcAb+) liver donors is a strategy utilized to increase organ availability. This study examined HBcAb+ transplantation practices to identify specific factors influencing outcomes. METHODS: Twenty-five HBcAb+ liver transplants were identified retrospectively among 868 adult transplants performed between 1 January 1997 and 31 December 2009. Twelve (48%) recipients had hepatitis C and five (20%) had hepatitis B. Patient and donor demographics, preoperative morbidity, transplant data and outcomes were examined. Statistical analysis was completed using Student's t-test or the Kaplan-Meier method. A P-value of <0.05 was considered significant. RESULTS: There was no difference in age, body mass index or comorbidities between HBcAb+ liver recipients and control subjects. Model for End-stage Liver Disease (MELD) scores of >30 were significantly more frequent in HBcAb+ liver recipients (32% vs. 15%; P= 0.04). All patients received immunoglobulin and longterm antiviral therapy as prophylaxis against graft hepatitis B resurgence. No patients who received HBcAb+ livers developed hepatitis B infection on follow-up. Overall survival at 30 days, 1 year and 5 years in HBcAb+ liver recipients was 92%, 74% and 74%, respectively, compared with 96%, 89% and 76%, respectively, in the control group (P= not significant, log-rank test). All except one of the deaths in the HBcAb+ liver recipient group occurred within 90 days postoperatively and in patients with MELD scores >30. CONCLUSIONS: The practice of transplanting HBcAb+ grafts incurs low risk for infection using current methods of prophylaxis. The highest mortality risk was in the early postoperative period, specifically in patients with very high MELD scores. This probably reflects the practice of using positive serology grafts in emergent situations.
BACKGROUND: The inclusion of hepatitis B core antibody-positive (HBcAb+) liver donors is a strategy utilized to increase organ availability. This study examined HBcAb+ transplantation practices to identify specific factors influencing outcomes. METHODS: Twenty-five HBcAb+ liver transplants were identified retrospectively among 868 adult transplants performed between 1 January 1997 and 31 December 2009. Twelve (48%) recipients had hepatitis C and five (20%) had hepatitis B. Patient and donor demographics, preoperative morbidity, transplant data and outcomes were examined. Statistical analysis was completed using Student's t-test or the Kaplan-Meier method. A P-value of <0.05 was considered significant. RESULTS: There was no difference in age, body mass index or comorbidities between HBcAb+ liver recipients and control subjects. Model for End-stage Liver Disease (MELD) scores of >30 were significantly more frequent in HBcAb+ liver recipients (32% vs. 15%; P= 0.04). All patients received immunoglobulin and longterm antiviral therapy as prophylaxis against graft hepatitis B resurgence. No patients who received HBcAb+ livers developed hepatitis B infection on follow-up. Overall survival at 30 days, 1 year and 5 years in HBcAb+ liver recipients was 92%, 74% and 74%, respectively, compared with 96%, 89% and 76%, respectively, in the control group (P= not significant, log-rank test). All except one of the deaths in the HBcAb+ liver recipient group occurred within 90 days postoperatively and in patients with MELD scores >30. CONCLUSIONS: The practice of transplanting HBcAb+ grafts incurs low risk for infection using current methods of prophylaxis. The highest mortality risk was in the early postoperative period, specifically in patients with very high MELD scores. This probably reflects the practice of using positive serology grafts in emergent situations.
Authors: M Jiménez-Pérez; A B Sáez-Gómez; L Mongil Poce; J M Lozano-Rey; J de la Cruz-Lombardo; J M Rodrigo-López Journal: Transplant Proc Date: 2010-10 Impact factor: 1.066
Authors: M Prieto; M D Gómez; M Berenguer; J Córdoba; J M Rayón; M Pastor; A García-Herola; D Nicolás; D Carrasco; J F Orbis; J Mir; J Berenguer Journal: Liver Transpl Date: 2001-01 Impact factor: 5.799
Authors: Cosme Manzarbeitia; David J Reich; Jorge A Ortiz; Kenneth D Rothstein; Victor R Araya; Santiago J Munoz Journal: Liver Transpl Date: 2002-06 Impact factor: 5.799
Authors: S F Dodson; S Issa; V Araya; T Gayowski; A Pinna; B Eghtesad; S Iwatsuki; E Montalvo; J Rakela; J J Fung Journal: Transplantation Date: 1997-12-15 Impact factor: 4.939
Authors: R C Dickson; J E Everhart; J R Lake; Y Wei; E C Seaberg; R H Wiesner; R K Zetterman; T L Pruett; M B Ishitani; J H Hoofnagle Journal: Gastroenterology Date: 1997-11 Impact factor: 22.682
Authors: R Bárcena; S Del Campo; G Moraleda; T Casanovas; M Prieto; M Buti; J M Moreno; V Cuervas; E Fraga; M De la Mata; A Otero; M Delgado; C Loinaz; C Barrios; M L G Dieguez; A Mas; J M Sousa; J I Herrero; R Muñoz; J F Avilés; A Gonzalez; M Rueda Journal: Transplant Proc Date: 2005-11 Impact factor: 1.066
Authors: Jose R Nery; Caio Nery-Avila; K Rajender Reddy; Robert Cirocco; Deborah Weppler; David M Levi; Seigo Nishida; Juan Madariaga; Tomoaki Kato; Phillip Ruiz; Eugene Schiff; Andreas G Tzakis Journal: Transplantation Date: 2003-04-27 Impact factor: 4.939
Authors: R Bárcena Marugán; F García-Hoz; M Vázquez Romero; R Nash; M Mateos; R González Alonso; M García González; A García Plaza Journal: Am J Gastroenterol Date: 2002-09 Impact factor: 10.864
Authors: Miguel Jiménez-Pérez; Rocío González-Grande; José Mostazo Torres; Carolina González Arjona; Francisco Javier Rando-Muñoz Journal: World J Gastroenterol Date: 2015-11-14 Impact factor: 5.742